{"id":"spirolactone","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute nephropathy","Acute pancreatitis","Anuria","Azotemia","Dehydration","Diabetes mellitus","Gout","Hepatic coma","Hypercalcemia","Hypercholesterolemia","Hyperkalemia","Hyperparathyroidism","Hyperuricemia","Hypochloremic alkalosis","Hypokalemia","Hypomagnesemia","Hyponatremia","Hypovolemia","Kidney disease","Metabolic acidosis, normal anion gap, acidifying salts","Neonatal hyperbilirubinemia","Secondary angle-closure glaucoma","Sympathectomy","Systemic lupus erythematosus"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2"},"_scrapedAt":"2026-03-28T05:30:13.464Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Aldosteronism","diseaseId":"aldosteronism","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ascites","diseaseId":"ascites","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic heart failure","diseaseId":"chronic-heart-failure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diagnostic Test for Primary Aldosteronism","diseaseId":"diagnostic-test-for-primary-aldosteronism","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Edema","diseaseId":"edema","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Edema due to Hepatic Cirrhosis","diseaseId":"edema-due-to-hepatic-cirrhosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Edema due to Nephrotic Syndrome","diseaseId":"edema-due-to-nephrotic-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hypertensive disorder","diseaseId":"hypertensive-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hypokalemia Prevention","diseaseId":"hypokalemia-prevention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Peripheral Edema due to Chronic Heart Failure","diseaseId":"peripheral-edema-due-to-chronic-heart-failure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pulmonary Edema due to Chronic Heart Failure","diseaseId":"pulmonary-edema-due-to-chronic-heart-failure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04760717","phase":"PHASE2","title":"Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2021-03-19","conditions":"Intracerebral Hemorrhage, Ischemic Stroke, Spironolactone","enrollment":160},{"nctId":"NCT01712620","phase":"PHASE2","title":"Spironolactone for Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2014-01-10","conditions":"Pulmonary Arterial Hypertension","enrollment":70},{"nctId":"NCT06678685","phase":"PHASE2, PHASE3","title":"Spironolactone Improved Children With Gene Mutations Related to NCOR","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-10-30","conditions":"NCOR Gene Mutations, Spironolactone, ASD","enrollment":2},{"nctId":"NCT07483151","phase":"","title":"Venous Congestion And Cognitive Dysfunction After Cardiac Surgery","status":"RECRUITING","sponsor":"Zhuan Zhang","startDate":"2024-11-01","conditions":"Intraoperative Venous Congestion And Cognitive Dysfunction After Cardiac Surgery","enrollment":110},{"nctId":"NCT07483177","phase":"PHASE1, PHASE2","title":"HEART: Pilot Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-05","conditions":"Thoracic Aortic Aneurysm","enrollment":50},{"nctId":"NCT07473895","phase":"PHASE2","title":"Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-04","conditions":"Acne Vulgaris","enrollment":40},{"nctId":"NCT07046975","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT07223502","phase":"PHASE3","title":"A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease","status":"RECRUITING","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-12-01","conditions":"Hypertension (HTN)","enrollment":30},{"nctId":"NCT07015671","phase":"PHASE3","title":"Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-07-01","conditions":"Bioequivalence Study in Healthy Subjects, PK/PD","enrollment":24},{"nctId":"NCT04582383","phase":"PHASE4","title":"Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-03-30","conditions":"Acne","enrollment":350},{"nctId":"NCT07043634","phase":"PHASE3","title":"A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sarfez Pharmaceuticals, Inc.","startDate":"2025-06-15","conditions":"Bioavailability Heathy Volunteers","enrollment":24},{"nctId":"NCT07431216","phase":"PHASE1, PHASE2","title":"A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression","status":"NOT_YET_RECRUITING","sponsor":"Lantern Pharma Inc.","startDate":"2026-04-01","conditions":"Histopathology Confirmed Supratentorial GBM at First Recurrence, IDHwt GBM, IDHm Grade 4 Astrocytoma","enrollment":68},{"nctId":"NCT07422948","phase":"NA","title":"Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-05","conditions":"Acute on Chronic Liver Failure","enrollment":113},{"nctId":"NCT05807139","phase":"PHASE1","title":"Spironolactone in Alcohol Use Disorder (SAUD)","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2023-07-13","conditions":"Alcohol Use Disorder","enrollment":20},{"nctId":"NCT07281014","phase":"PHASE4","title":"Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-01-27","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT07415811","phase":"NA","title":"Spironolactone and XPB-1 Integrity in the TFIIH Complex","status":"ENROLLING_BY_INVITATION","sponsor":"University of Sao Paulo General Hospital","startDate":"2024-07-24","conditions":"HIV","enrollment":12},{"nctId":"NCT03593317","phase":"PHASE2","title":"Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-12-20","conditions":"Arrhythmogenic Right Ventricular Dysplasia","enrollment":120},{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":"Severe Aortic Valve Stenosis","enrollment":25},{"nctId":"NCT06004830","phase":"PHASE2","title":"Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-11-06","conditions":"Alcohol Use Disorder, Hiv","enrollment":30},{"nctId":"NCT07331220","phase":"NA","title":"Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-12-30","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":310},{"nctId":"NCT07328230","phase":"NA","title":"Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2022-08-01","conditions":"Idiopathic Hyperaldosteronism, Hyperaldosteronism","enrollment":172},{"nctId":"NCT03429946","phase":"PHASE4","title":"Hypoglycemia and Autonomic Nervous System Function-B","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2013-07-17","conditions":"Hypoglycemia, Healthy","enrollment":28},{"nctId":"NCT07304817","phase":"PHASE2","title":"Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2026-02","conditions":"CKD, Cardiovascular Diseases, Heart Failure","enrollment":100},{"nctId":"NCT07285187","phase":"","title":"Venous Congestion And Delirium After Cardiac Surgery","status":"RECRUITING","sponsor":"Zhuan Zhang","startDate":"2024-11-01","conditions":"Intraoperative, Venous Congestion, Postoperative Delirium (POD)","enrollment":120},{"nctId":"NCT05561361","phase":"","title":"The Effect of SAAE on Vascular Endothelial Function in PA Patients","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2022-10-01","conditions":"Primary Aldosteronism","enrollment":200},{"nctId":"NCT04251780","phase":"","title":"Tissue K+ in Primary Hyperaldosteronism","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2018-01-01","conditions":"Primary Hyperaldosteronism, Electrolyte Disturbance","enrollment":21},{"nctId":"NCT04633005","phase":"PHASE2","title":"Polypill Strategy for Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-11-15","conditions":"Heart Failure","enrollment":212},{"nctId":"NCT07235891","phase":"PHASE4","title":"Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Alexandria University","startDate":"2025-11-20","conditions":"Retinal Nerve Fiber Layer Thickness, Chronic Kidney Disease","enrollment":40},{"nctId":"NCT07232277","phase":"","title":"Venous Congestion and Cardiac Surgery-Associated Acute Kidney Injury","status":"RECRUITING","sponsor":"Zhuan Zhang","startDate":"2024-10-15","conditions":"Intraoperative, Venous Congestion, Cardiac Surgery-associated Acute Kidney Injury","enrollment":114},{"nctId":"NCT04980716","phase":"PHASE3","title":"Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-06-01","conditions":"Non-small Cell Lung Cancer, Cardiovascular Complication","enrollment":524},{"nctId":"NCT04522739","phase":"PHASE4","title":"Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-09-06","conditions":"Mild Cognitive Impairment, Alzheimer Disease","enrollment":25},{"nctId":"NCT07041281","phase":"PHASE2","title":"Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-10-16","conditions":"Preeclampsia, Gestational Hypertension","enrollment":204},{"nctId":"NCT05014087","phase":"PHASE2","title":"Digoxin In Treatment of Alcohol Associated Hepatitis","status":"TERMINATED","sponsor":"Yale University","startDate":"2021-10-08","conditions":"Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders","enrollment":23},{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":"Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction","enrollment":4936},{"nctId":"NCT05754684","phase":"PHASE2","title":"Quadruple Immunotherapy for Neuroblastoma","status":"RECRUITING","sponsor":"Hong Kong Children's Hospital","startDate":"2022-01-01","conditions":"Neuroblastoma Recurrent","enrollment":29},{"nctId":"NCT01552044","phase":"PHASE1, PHASE2","title":"Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2012-01","conditions":"Central Serous Chorioretinitis","enrollment":17},{"nctId":"NCT07137364","phase":"","title":"Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism","status":"RECRUITING","sponsor":"Third Military Medical University","startDate":"2022-05-01","conditions":"Primary Aldosteronism, Hypertension","enrollment":350},{"nctId":"NCT07130175","phase":"NA","title":"Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure (RFCA for PMVT-HF)","status":"COMPLETED","sponsor":"Qian Feng","startDate":"2022-12-31","conditions":"Polymorphic Ventricular Tachycardia, Heart Failure","enrollment":118},{"nctId":"NCT05676684","phase":"PHASE2, PHASE3","title":"Dapagliflozin With or Without Spironolactone for HFpEF","status":"COMPLETED","sponsor":"Universidade do Porto","startDate":"2022-09-15","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":108},{"nctId":"NCT05411991","phase":"PHASE4","title":"Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2022-06-12","conditions":"Acute Heart Failure, Diuretics Drug Reactions","enrollment":107},{"nctId":"NCT03068910","phase":"EARLY_PHASE1","title":"Hyperandrogenemia and Altered Day-night LH Pulse Patterns","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2016-07-21","conditions":"Hyperandrogenism, Polycystic Ovary Syndrome, Puberty","enrollment":32},{"nctId":"NCT04723862","phase":"EARLY_PHASE1","title":"Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2021-11-12","conditions":"Hyperandrogenism, Polycystic Ovary Syndrome, Puberty","enrollment":32},{"nctId":"NCT06247267","phase":"","title":"The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population","status":"RECRUITING","sponsor":"Walter Reed National Military Medical Center","startDate":"2021-03-09","conditions":"Hypogonadism, Gender Identity Dysphoria","enrollment":75},{"nctId":"NCT04676646","phase":"PHASE4","title":"Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-08","conditions":"Hyperkalaemia, Heart Failure With Reduced Ejection Fraction","enrollment":366},{"nctId":"NCT07020104","phase":"NA","title":"The Role of Skin Sodium Accumulation in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2025-01-07","conditions":"Chronic Kidney Diseases","enrollment":60},{"nctId":"NCT04901975","phase":"PHASE1, PHASE2","title":"Fibrosis and the Fontan","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-02-11","conditions":"Single-ventricle","enrollment":145},{"nctId":"NCT03929718","phase":"EARLY_PHASE1","title":"Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Piedmont Healthcare","startDate":"2019-04-24","conditions":"AFib","enrollment":50},{"nctId":"NCT05501080","phase":"NA","title":"The Effect of SAAE on Ventricular Remodeling in PA Patients","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2022-09-01","conditions":"Primary Aldosteronism","enrollment":112},{"nctId":"NCT06495710","phase":"NA","title":"Arterial Stiffness and Blood Pressure","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-05-01","conditions":"Hypertension, Vascular Stiffness, Aging","enrollment":228},{"nctId":"NCT05637853","phase":"PHASE4","title":"Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Göteborg University","startDate":"2022-10-22","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":60},{"nctId":"NCT05797558","phase":"NA","title":"Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment","status":"RECRUITING","sponsor":"Göteborg University","startDate":"2023-04-28","conditions":"Primary Hyperaldosteronism Due to Adrenal Adenoma","enrollment":80},{"nctId":"NCT04727073","phase":"PHASE3","title":"Spironolactone in the Treatment of Heart Failure","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-11-01","conditions":"Heart Failure with Mid-range Ejection Fraction, Heart Failure with Preserved Ejection Fraction","enrollment":743},{"nctId":"NCT03576755","phase":"PHASE1, PHASE2","title":"Spironolactone Therapy In Young Women With NASH","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-01-09","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":20},{"nctId":"NCT04283656","phase":"PHASE1","title":"Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-01-04","conditions":"Transgender Health, Gender Dysphoria, Transgender Women","enrollment":8},{"nctId":"NCT06641284","phase":"","title":"Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With Spironolactone","status":"COMPLETED","sponsor":"Ahmad Abdullah Salawi","startDate":"2023-10-01","conditions":"Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II","enrollment":509},{"nctId":"NCT06205407","phase":"PHASE1","title":"A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-26","conditions":"Healthy Participants","enrollment":42},{"nctId":"NCT03020303","phase":"PHASE3","title":"Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2017-07-07","conditions":"Endstage Renal Disease","enrollment":2538},{"nctId":"NCT05092984","phase":"PHASE3","title":"Evaluation of Spironolactone Efficacy in Patient with Rheumatoid Arthritis (RA)","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2022-06-22","conditions":"Rheumatoid Arthritis","enrollment":154},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT05933265","phase":"PHASE1, PHASE2","title":"Study of LP-184 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Lantern Pharma Inc.","startDate":"2023-06-09","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, GBM","enrollment":175},{"nctId":"NCT02378805","phase":"","title":"Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome","status":"RECRUITING","sponsor":"University Hospital Goettingen","startDate":"1995-07","conditions":"Alport Syndrome, Hereditary Kidney Disease, Pediatric Kidney Disease","enrollment":800},{"nctId":"NCT04142788","phase":"PHASE4","title":"RELieving Increasing oEdema Due to Heart Failure","status":"TERMINATED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2020-08-26","conditions":"Heart Failure，Congestive","enrollment":19},{"nctId":"NCT03122834","phase":"","title":"Effect of Genetic Polymorphism on the Clinical Outcome of Patients With Heart Failure","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-04-15","conditions":"Heart Failure","enrollment":246},{"nctId":"NCT06377449","phase":"NA","title":"Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients","status":"RECRUITING","sponsor":"Saint Petersburg State University, Russia","startDate":"2024-05-15","conditions":"Ischemic Heart Disease, Aortic Stenosis, Severe, Aortic Insufficiency","enrollment":186},{"nctId":"NCT05010707","phase":"PHASE2","title":"Transgender Estradiol Affirming Therapy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-08-02","conditions":"Transgenderism","enrollment":39},{"nctId":"NCT06523465","phase":"PHASE4","title":"Statin Combined with Amlodipine Treats Primary Aldosteronism","status":"RECRUITING","sponsor":"Third Military Medical University","startDate":"2024-09-10","conditions":"Primary Aldosteronism, Statin, Mineralocorticoid Receptor Antagonist","enrollment":180},{"nctId":"NCT05318755","phase":"","title":"China Gender-affirming Hormone Therapy Study","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2022-04-16","conditions":"Transgender, Gender Incongruence","enrollment":240},{"nctId":"NCT02901184","phase":"PHASE3","title":"Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2017-11-23","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":2000},{"nctId":"NCT05849766","phase":"PHASE3","title":"Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction","status":"COMPLETED","sponsor":"October 6 University","startDate":"2023-04-27","conditions":"Dilated Cardiomyopathy","enrollment":150},{"nctId":"NCT03048825","phase":"PHASE3","title":"Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2018-02-01","conditions":"ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction","enrollment":7264},{"nctId":"NCT05663892","phase":"PHASE4","title":"Drug-Drug Interaction Study in Trans Women Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Maple Leaf Research","startDate":"2022-11-23","conditions":"Hiv, Transgenderism","enrollment":45},{"nctId":"NCT04331691","phase":"PHASE4","title":"Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2020-11-16","conditions":"Resistant Hypertension","enrollment":118},{"nctId":"NCT05195164","phase":"","title":"The Effects of Orchiectomy and Age on Vascular and Metabolic Health in Older Versus Younger Transgender Women","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2021-03-22","conditions":"Transgender, Gender Identity, Vascular Stiffness","enrollment":17},{"nctId":"NCT04066283","phase":"","title":"Effects of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Women","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-04-17","conditions":"Transgender, Gender Identity, Vascular Stiffness","enrollment":29},{"nctId":"NCT04100083","phase":"PHASE4","title":"Spironolactone for Hidradenitis Suppurativa","status":"WITHDRAWN","sponsor":"Medical University of South Carolina","startDate":"2020-09-21","conditions":"Hidradenitis Suppurativa","enrollment":""},{"nctId":"NCT03874338","phase":"","title":"CLEAR SYNERGY Neutrophil Substudy","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-03-04","conditions":"Neutrophils.Hypersegmented | Bld-Ser-Plas, STEMI - ST Elevation Myocardial Infarction","enrollment":322},{"nctId":"NCT06091475","phase":"NA","title":"Therapy to Maintain Remission in Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2023-12-02","conditions":"Heart Failure, Cardiomyopathy, Dilated, Cardiomyopathies","enrollment":50},{"nctId":"NCT03953209","phase":"PHASE1","title":"Spironolactone for the Treatment of Melasma","status":"WITHDRAWN","sponsor":"Medical University of South Carolina","startDate":"2020-03-05","conditions":"Melasma","enrollment":""},{"nctId":"NCT06457074","phase":"PHASE4","title":"Finerenone for Patients With Primary Aldosteronism (FAIRY)","status":"RECRUITING","sponsor":"Qifu Li","startDate":"2024-06-04","conditions":"Primary Aldosteronism","enrollment":306},{"nctId":"NCT06579053","phase":"PHASE1","title":"Bioequivalence Study of Spironolactone Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"SPH Sine Pharmaceutical Laboratories Co., Ltd.","startDate":"2023-03-22","conditions":"Bioequivalence Study","enrollment":64},{"nctId":"NCT04409431","phase":"NA","title":"Effects of Adrenal Artery Ablation and Spironolactone in Patients With Primary Aldosteronism","status":"RECRUITING","sponsor":"Third Military Medical University","startDate":"2019-12-01","conditions":"Primary Aldosteronism, Hypertension","enrollment":60},{"nctId":"NCT01294319","phase":"PHASE2","title":"Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2011-01-24","conditions":"Cortisol Resistance, Negative Feedback, ACTH","enrollment":51},{"nctId":"NCT06499948","phase":"PHASE4","title":"Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients with Alport Syndrome (COMBINE-ALPORT)","status":"RECRUITING","sponsor":"Stefan Lujinschi","startDate":"2024-02-26","conditions":"Alport Syndrome, Thin Basement Membrane Disease, Alport Nephropathy","enrollment":34},{"nctId":"NCT03344159","phase":"PHASE4","title":"Spironolactone Therapy in Chronic Stable Right HF Trial","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2018-04-01","conditions":"Chronic Right-Sided Heart Failure, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Primary, 2","enrollment":15},{"nctId":"NCT04643691","phase":"PHASE2","title":"Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2020-09-11","conditions":"COVID-19, ARDS","enrollment":78},{"nctId":"NCT05924620","phase":"PHASE4","title":"Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2023-06-21","conditions":"Primary Aldosteronism","enrollment":60},{"nctId":"NCT06413082","phase":"PHASE3","title":"Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment","status":"COMPLETED","sponsor":"Ospedale San Raffaele","startDate":"2021-02-15","conditions":"Hypertension, Genetic Predisposition, Drug Effect","enrollment":38},{"nctId":"NCT04199910","phase":"","title":"4beta-hydroxycholesterol in Cirrhosis","status":"SUSPENDED","sponsor":"University of Oulu","startDate":"2019-12-01","conditions":"Cirrhosis, Liver","enrollment":120},{"nctId":"NCT05394142","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)","status":"RECRUITING","sponsor":"Fundació Sant Joan de Déu","startDate":"2022-05-24","conditions":"Polycystic Ovary Syndrome (PCOS)","enrollment":364},{"nctId":"NCT03652623","phase":"PHASE1, PHASE2","title":"Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study","status":"COMPLETED","sponsor":"Hektoen Institute for Medical Research","startDate":"2018-07-23","conditions":"HIV/AIDS, Gender, Behavior and Behavior Mechanisms","enrollment":49},{"nctId":"NCT06233695","phase":"","title":"Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-10-15","conditions":"Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II","enrollment":100},{"nctId":"NCT06275763","phase":"PHASE4","title":"Optimal Medical Treatment of Difficult-to-treat Hypertension","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2023-10-20","conditions":"Hypertension","enrollment":2500},{"nctId":"NCT06035978","phase":"PHASE4","title":"Determination of Drug Levels for Pharmacotherapy of Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Ostrava","startDate":"2024-03","conditions":"Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction","enrollment":100},{"nctId":"NCT06204640","phase":"PHASE3","title":"SPironolactONe for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Caen","startDate":"2024-03-01","conditions":"Atrial Fibrillation Recurrent","enrollment":580},{"nctId":"NCT06164379","phase":"PHASE4","title":"Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-12-16","conditions":"Primary Aldosteronism","enrollment":150},{"nctId":"NCT01422759","phase":"NA","title":"Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2016-12-09","conditions":"Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome","enrollment":20},{"nctId":"NCT04075149","phase":"EARLY_PHASE1","title":"Does Treatment of Androgen Excess Using Spironolactone Improve Ovulatory Rates in Girls With Androgen Excess?","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2019-12-18","conditions":"Polycystic Ovary Syndrome, Puberty Disorders, Ovulation Disorder","enrollment":24},{"nctId":"NCT03777319","phase":"PHASE1","title":"Spironolactone Versus Prednisolone in DMD","status":"TERMINATED","sponsor":"Kevin Flanigan","startDate":"2018-12-05","conditions":"Muscular Dystrophy, Duchenne","enrollment":2},{"nctId":"NCT01848639","phase":"PHASE3","title":"ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2013-06","conditions":"End Stage Renal Failure on Dialysis","enrollment":823},{"nctId":"NCT05287100","phase":"NA","title":"To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation.","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2022-01-01","conditions":"Cirrhosis, Liver","enrollment":35}],"_emaApprovals":[],"_faersSignals":[{"count":27,"reaction":"DYSPNOEA"},{"count":22,"reaction":"FATIGUE"},{"count":17,"reaction":"DRUG INEFFECTIVE"},{"count":15,"reaction":"DIARRHOEA"},{"count":14,"reaction":"CONDITION AGGRAVATED"},{"count":13,"reaction":"DIZZINESS"},{"count":13,"reaction":"NAUSEA"},{"count":13,"reaction":"PAIN IN EXTREMITY"},{"count":12,"reaction":"HEADACHE"},{"count":11,"reaction":"OFF LABEL USE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":414,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_1","status":"active","brandName":"spirolactone","genericName":"spirolactone","companyName":"Second Xiangya Hospital of Central South University","companyId":"second-xiangya-hospital-of-central-south-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Spirolactone is a small molecule with a cyclic ester attached to another ring system, classified as a synthetic steroid. It is an antimineralocorticoid, functioning as an antagonist of the mineralocorticoid receptor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}